Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Explore this paper's citation graph
Summary
This study showed an association between the FCGR3A genotype and clinical and molecular responses to rituximab, and will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas.
- Type
- article
- Published
- 2002-02-01
- Cited by
- 2,042
- References
- 41
- Access
- Open access
- OpenAlex
- https://openalex.org/W2044360617
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:10367949
Keywords
Fc receptor, Monoclonal antibody, Antibody, Monoclonal, Immunology
References
- Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.
- Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
- Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
- Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.
- Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.
- IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
- Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations.
- High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*
- Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.
- Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED).
- Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
- The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
- Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
- Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
- European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
- Immunoglobulin G Fc-receptor (FcgammaR) IIA and IIIB polymorphisms related to disability in MS.
- Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
- Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms
Cited by
- The future of antibody therapy.
- Immune complex-mediated antigen presentation induces tumor immunity.
- Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
- Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR.
- Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab.
- Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells1
- Rituximab in autoimmune diseases.
- Use of biological response modifiers to enhance the action of Rituximab.
- Predicting drug response and toxicity based on gene polymorphisms.
- Generation of Rituximab Polymer May Cause Hyper-Cross-linking–Induced Apoptosis in Non-Hodgkin's Lymphomas
- Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIa
- Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia1
- Neutrophils in antibody-based immunotherapy of cancer
- Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
- Translational Mini‐Review Series on B Cell‐Directed Therapies: B cell‐directed therapy for autoimmune diseases
- The role of natural killer cells in cancer therapy.
- Bispecific antibodies for cancer therapy
- New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies
- Modulation of antibody effector function.
Related papers
- Monoclonal Antibody 1C11 Mouse Monoclonal Antibody Against Mortalin
- Preparation,Characterization and application of monoclonal antibodies to recombinant human interferon—α2a
- Anti-Human HB-EGF Monoclonal Antibody
- Chicken Antibodies: A Tool to Avoid Interference by Human Anti-Mouse Antibodies in ELISA After In Vivo Treatment With Murine Monoclonal Antibodies
- Mouse monoclonal antibodies at the red cell surface--I. Generation of EAC4 and interaction with C1.
- Purification of immunoreactive radiolabeled monoclonal antibodies with anti-idiotypic monoclonal antibodies.
- Rat monoclonal antibodies. I. Rapid purification from in vitro culture supernatants.
- Preparation of peroxidase: antiperoxidase (PAP) complexes for immunohistological labeling of monoclonal antibodies.
- Suppressor T cell changes in active multiple sclerosis: analysis with three different monoclonal antibodies.
- Production of a new anti-A monoclonal reagent